Japanese Drug Wholesaler Suzuken Reports Lower Profits
This article was originally published in PharmAsia News
Major Japanese drug wholesaler Suzuken reported lower sales and profits for the interim fiscal year ending September. The group sales increased by 3.8 percent to ¥795.9 billion, however, business profit reduced by 29.7 percent to ¥6.46 billion, regular profit was down by 15.3 percent to ¥13.4 billion and net profit dropped by 45 percent to ¥4.8 billion. According to the company, compared to previous estimations, drug prices are lower and the operation costs for distribution centers are higher. Suzuken President Hiroshi Oda also cited hospitals' buying power and competition among drug wholesalers. (Click here for more - Japanese language
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.